30 closest matches · ranked by relevance
Atypical Hemolytic-Uremic Syndrome
Primary: Percentage of Patients With Complete TMA Response — 73.2 Percentage of Participants
Atypical Hemolytic Uremic Syndrome
Primary: Percentage of Patients With TMA Event-free Status — 80 Percentage of Participants
Atypical Hemolytic Uremic
Primary: Percentage of Participants With a Complete Thrombotic Microangiopathy (TMA) Response — 64.0 percentage of participants
Atypical Hemolytic-Uremic Syndrome
Primary: Proportion of Patients With Complete TMA Response — 63.6 Percentage of Participants
Atypical Hemolytic Uremic Syndrome (aHUS)
Primary: Percentage Of Complement Inhibitor Treatment-naïve Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26 — 77.8; 94.4; 88.9; 83.3 percentage of…
Atypical Hemolytic Uremic Syndrome
Primary: Platelet Count Change From Baseline to 26 Weeks — 65.18 10^9 cells/L — p=<0.0001
Atypical Hemolytic Uremic Syndrome
Primary: Percentage of Patients With TMA Event-free Status — 80 Percentage of Participants
Atypical Hemolytic Uremic Syndrome
Primary: Platelet Count Change From Baseline to 26 Weeks — 65.18 10^9 cells/L — p=<0.0001
Thrombotic Microangiopathies · Atypical Hemolytic Uremic Syndrome · Multiple Organ Dysfunction Syndrome
Primary: Survival — 15 Participants — p=<0.0001
Atypical Hemolytic Uremic Syndrome (aHUS)
Primary: Percentage Of Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26 — 53.6; 83.9; 76.8; 58.9 percentage of participants
Antiphospholipid Antibody Syndrome · End Stage Renal Disease
Primary: Number of Patients With Prevention of Catastrophic Antiphospholipid Antibody Syndrome (CAPS) After Kidney Transplant — 1 Participants
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Primary: ADAMTS-13 Activity Levels — 0.1439; NA; NA; 0.5418 international units(IU)/ml
Kidney Transplant
Primary: Number of Subjects With Antibody-Mediated Rejection (AMR) in the First 3 Months After Living Donor Kidney Transplantation — 2 Participants
Thrombotic Thrombocytopenic Purpura (TTP)
Primary: Number of Participants With Acute Thrombotic Thrombocytopenic Purpura (TTP) Events During Prophylactic Treatment — 0; 0; 1 Participants
Thrombotic Microangiopathies
Primary: Assess the Safety and Tolerability of Multiple-dose Administration of OMS721 in Participants With TMA — 0; 0; 27 Participants
Kidney; Complications, Allograft
Primary: Baseline eGFR (Estimated Glomerular Filtration Rate) — 30.04; 30.04 mL/min/1.73 m2
Acquired Thrombotic Thrombocytopenic Purpura
Primary: Percentage of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Related Events — 37.9; 8.2 percentage of participants
Acquired Thrombotic Thrombocytopenic Purpura
Primary: Time-to-response of Treatment Defined by a Confirmed Recovery of Platelets ≥ 150,000/µL — 2.4; 4.3; 3; 4.9 days — p== 0.005
Transplant-Associated Thrombotic Microangiopathy
Primary: Pegcetacoplan Pharmacokinetic (PK) Parameter Area Under the Curve Limited to the End of Dosing Interval (AUC0-tau) — 14934.65; 20089.79; 36208.37 µg*h/mL
Thrombotic Thrombocytopenic Purpura
Primary: Percentage of Participants Who Achieved Remission Without Requirement of Therapeutic Plasma Exchange During Overall Study Period — 93.5 percentage of participants
Aplastic Anemia
Primary: Participants no Longer Meeting Criteria for Severe Aplastic Anemia. — 18; 17; 9; 9 participants
IgA Nephropathy · Lupus Nephritis · Membranous Nephropathy
Primary: Part A: Change From Baseline in Proteinuria at Week 48 — -0.1364; 0.3560; 0.3430; -2.0347 ratio
Warm Autoimmune Hemolytic Anemia · Cold Agglutinin Disease
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity — 5; 5; 7; 6 Participants
Antithrombin III Deficiency
Primary: Incidence of Thromboembolic Events Acute Deep Venous Thrombosis (DVT) and/or Thromboembolic Events Other Than Acute Deep Venous Thrombosis (DVT) — 0 Participants
Thrombotic Microangiopathies
Primary: Percent of Total Doses of Defibrotide That Were Missed [Feasibility] — 0.7 percentage of missed doses
Thrombotic Microangiopathy
Primary: Participants With Thrombotic Microangiopathy (TMA) Response — 7 Participants
Renal Disease
Primary: Number of Participants With Allograft Rejection — 7 Participants
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Measurement of Serum Lactate Dehydrogenase (LDH) — 2913; 3056; 1453; 564 U/L
Hemophagocytic Lymphohistiocytosis · X-Linked Lymphoproliferative Disorders · Chediak-Higashi Syndrome
Primary: Number of Subjects With Mixed Chimerism — 3; 8; 4 participants
Antithrombin Deficiency, Congenital
Primary: Incidence of Thromboembolic Events Acute Deep Venous Thrombosis (DVT) and/or Thromboembolic Events Other Than Acute Deep Vein Thrombosis (DVT). — 1 participants